Incruse Ellipta (umeclidinium) is a prescription drug that’s used to treat chronic obstructive pulmonary disease (COPD). The drug comes as a dry powder that you inhale. It’s typically used once per ...
The U.S. Food and Drug Administration has approved GlaxoSmithKline’s Incruse Ellipta (umeclidinium) as a treatment for patients with chronic obsessive pulmonary disease, according to a Medscape report ...
Incruse Ellipta (umeclidinium) is a prescription drug used for treating chronic obstructive pulmonary disease (COPD). Incruse Ellipta can cause side effects that range from mild to serious. Examples ...
The FINANCIAL — GlaxoSmithKline plc on October 20 announced positive results from two head-to-head studies directly comparing the efficacy and safety of Incruse Ellipta (umeclidinium) to two available ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback